References
- Tucker MA, Goldstein AM. Melanoma etiology: where are we?. Oncogene 2003; 22:3042 - 3052
- Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, et al. Prevalence of p16 and Cdk4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998; 7:209 - 216
- Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK4a binding domain of Cdk4 in familial melanoma. Nat Genet 1996; 12:97 - 99
- Hayward N. New developments in melanoma genetics. Curr Oncol Rep 2000; 2:300 - 306
- Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B or one of their downstream targets. Genes Chromosomes Cancer 1998; 22:157 - 163
- Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85:27 - 37
- Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997; 11:2822 - 2834
- Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400:468 - 472
- Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 2000; 157:967 - 972
- Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 2001; 117:1483 - 1489
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949 - 954
- Rane SG, Cosenza SC, Mettus RV, Reddy EP. Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol 2002; 22:644 - 656
- Cangiarella J, Symmans WF, Shapiro RL, Roses DF, Cohen JM, Chhieng D, et al. Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes. Cancer 2000; 90:162 - 166
- Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22:3551 - 3555
- Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323 - 331
- Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269:1281 - 1284
- Sotillo R, Garcia JF, Ortega S, Martin J, Dubus P, Barbacid M, et al. Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci USA 2001; 98:13312 - 13317
- Hacker E, Muller HK, Irwin N, Gabrielli B, Lincoln D, Pavey S, et al. Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice. Cancer Res 2006; 66:2946 - 2952
- Kramer TR, Powell MB, Wilson MM, Salvatore J, Grossniklaus HE. Pigmented uveal tumours in a transgenic mouse model. Br J Ophthalmol 1998; 82:953 - 960
- Meier F, Satyamoorthy K, Nesbit M, Hsu MY, Schittek B, Garbe C, et al. Molecular events in melanoma development and progression. Front Biosci 1998; 3:1005 - 1010
- Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 2005; 10:2986 - 3001